Last month, the United States Food and Drug Administration (FDA) approved a new wearable device for treating pancreatic cancer. This device, called Optune | Cancer ...
Add Yahoo as a preferred source to see more of our stories on Google. WASHINGTON (DC News Now) — September is Prostate Cancer Awareness Month, and according to the National Cancer Institute (NCI), ...
ImmunityBio Inc. IBRX shares are up Tuesday following the announcement that the National Comprehensive Cancer Network (NCCN) ...
SAN FRANCISCO, May 22, 2025 /PRNewswire/ -- OncoSwab, a biotechnology company focused on early detection of cancer through non-invasive molecular testing, today announced it has entered into a ...
Johnson & Johnson (NYSE:JNJ) today announced results from an open-label, multicenter Phase 1 study evaluating an investigational intravesical drug-releasing system with erdafitinib (Erda-iDRS) in ...
A recent breakthrough study highlights how a simple at-home urine test could accurately detect prostate cancer. Researchers from Vanderbilt University and the University of Michigan suggest this ...
Recurrences of low-, intermediate-, or high-/very high-risk tumors were again low, intermediate, or high risk in 74%, 62%, and 44% of cases, respectively. Recurrent non-muscle invasive bladder cancer ...
GlobalData on MSN
J&J reports positive data for Erda-iDRS in bladder cancer
Erda-iDRS delivers erdafitinib into the bladder over three months, enabling localised therapy and reducing systemic exposure.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results